Filing Flows › Travere Therapeutics (TVTX) › Recalls, complaints & regulation
Travere Therapeutics (TVTX): clinical trials
Travere Therapeutics (TVTX) beyond its filings: 5 active clinical trials.
Travere Therapeutics' latest quarter
Travere Therapeutics, Q3 2026: revenue $225M (+36% year over year), operating margin -30.3%, net loss $52.3M, operating cash flow $98.2M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Travere Therapeutics have?
5 active studies on ClinicalTrials.gov, 2 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.